NewAmsterdam Pharma Company N.V (NAMS) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $28.45: Quality below floor (3.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 4.1:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 95.50; Below-average business quality; Negative price momentum.
NewAmsterdam Pharma is a late-stage biopharma with no approved products, focused entirely on obicetrapib, an oral CETP inhibitor for LDL-C lowering in cardiometabolic disease patients. It reported a net loss of $203.8 million in 2025 with $728.9 million in cash; the EMA accepted... Read more
Sell if holding. Engine safety override at $28.45: Quality below floor (3.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 4.1:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 95.50; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.9/10, moderate confidence.
Passes 5/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and earnings proximity 7d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductobicetrapib10-K Item 1A: 'We are dependent on the success of our only product candidate, obicetrapib'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers·1 ceiling hit
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $28.45: Quality below floor (3.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 4.1:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 95.50; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $27.01. Score 4.9/10, moderate confidence.
Take-profit target: $43.02 (+51.2% upside). Prior stop was $27.01. Stop-loss: $27.01.
Concentration risk — Product: obicetrapib; Quality below floor (3.1 < 4.0).
NewAmsterdam Pharma Company N.V trades at a P/E of N/A (forward -20.7). TrendMatrix value score: 9.0/10. Verdict: Sell.
22 analysts cover NAMS with a consensus score of 4.3/5. Average price target: $49.
What does NewAmsterdam Pharma Company N.V do?NewAmsterdam Pharma is a late-stage biopharma with no approved products, focused entirely on obicetrapib, an oral CETP...
NewAmsterdam Pharma is a late-stage biopharma with no approved products, focused entirely on obicetrapib, an oral CETP inhibitor for LDL-C lowering in cardiometabolic disease patients. It reported a net loss of $203.8 million in 2025 with $728.9 million in cash; the EMA accepted MAAs from partner Menarini for review in August 2025.